Mo Qatanani Sells 8,406 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 8,406 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $44.48, for a total value of $373,898.88. Following the completion of the sale, the insider directly owned 100,558 shares in the company, valued at approximately $4,472,819.84. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Mo Qatanani also recently made the following trade(s):

• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The shares were sold at an average price of $45.20, for a total transaction of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Trading Up 2.9%

Shares of SRRK traded up $1.31 during mid-day trading on Wednesday, hitting $46.05. The company had a trading volume of 1,173,163 shares, compared to its average volume of 836,796. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $48.28. The business’s 50-day simple moving average is $43.23 and its 200-day simple moving average is $37.16. The stock has a market cap of $4.70 billion, a PE ratio of -14.62 and a beta of 0.63. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the prior year, the firm earned ($0.66) EPS. Sell-side analysts forecast that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Institutional Trading of Scholar Rock

Several large investors have recently bought and sold shares of SRRK. Moody Aldrich Partners LLC grew its holdings in Scholar Rock by 53.5% during the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after purchasing an additional 35,481 shares in the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lifted its holdings in Scholar Rock by 145.3% in the 2nd quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 769,442 shares of the company’s stock worth $27,254,000 after buying an additional 455,753 shares in the last quarter. Norges Bank purchased a new position in Scholar Rock in the 2nd quarter valued at about $41,628,000. Voya Investment Management LLC grew its stake in shares of Scholar Rock by 18.1% during the third quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock valued at $16,503,000 after acquiring an additional 67,839 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Scholar Rock by 4.3% during the second quarter. American Century Companies Inc. now owns 692,676 shares of the company’s stock valued at $24,535,000 after acquiring an additional 28,749 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Wall Street Analysts Forecast Growth

SRRK has been the subject of a number of research reports. BMO Capital Markets reissued an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a research report on Friday, November 14th. UBS Group started coverage on Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock. Bank of America started coverage on Scholar Rock in a report on Thursday, October 9th. They set a “buy” rating and a $53.00 target price for the company. Piper Sandler cut their price target on shares of Scholar Rock from $52.00 to $51.00 and set an “overweight” rating on the stock in a report on Wednesday, September 24th. Finally, HC Wainwright reduced their price target on shares of Scholar Rock from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, September 23rd. Four research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $50.14.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).